TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors are reported in a recent Bisichem Co. Ltd. patent as potentially useful for the treatment of cancer, obesity, diabetes, fibrosis, autoimmune diseases and vascular disorders.